<MedlineCitation Status="Completed">
<MedlineID>10011935</MedlineID>
<PMID>369676</PMID>
<DateCreated>
<Year>1979</Year>
<Month>05</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>05</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0008-543X</ISSN>
<JournalIssue>
<Volume>43</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1979</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Alternating chemotherapy and irradiation in the treatment of advanced Hodgkin's disease.</ArticleTitle>
<Pagination>
<MedlinePgn>472-81</MedlinePgn>
</Pagination>
<AuthorList>
<Author>
<LastName>Hoppe</LastName>
<ForeName>R T</ForeName>
<Initials>RT</Initials>
</Author>
<Author>
<LastName>Portlock</LastName>
<ForeName>C S</ForeName>
<Initials>CS</Initials>
</Author>
<Author>
<LastName>Glatstein</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author>
<LastName>Rosenberg</LastName>
<ForeName>S A</ForeName>
<Initials>SA</Initials>
</Author>
<Author>
<LastName>Kaplan</LastName>
<ForeName>H S</ForeName>
<Initials>HS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Clinical Trial</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Cancer</MedlineTA>
<NlmUniqueID>0374236</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>148-82-3</RegistryNumber>
<NameOfSubstance>Melphalan</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>51-75-2</RegistryNumber>
<NameOfSubstance>Mechlorethamine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>53-03-2</RegistryNumber>
<NameOfSubstance>Prednisone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>57-22-7</RegistryNumber>
<NameOfSubstance>Vincristine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>671-16-9</RegistryNumber>
<NameOfSubstance>Procarbazine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>865-21-4</RegistryNumber>
<NameOfSubstance>Vinblastine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>Adolescence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y">administration &#38; dosage</QualifierName>
<QualifierName>adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Bone Marrow</DescriptorName>
<QualifierName>drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Clinical Trials</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Comparative Study</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Hodgkin Disease</DescriptorName>
<QualifierName MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Human</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Mechlorethamine</DescriptorName>
<QualifierName>administration &#38; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Melphalan</DescriptorName>
<QualifierName>administration &#38; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Middle Age</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Prednisone</DescriptorName>
<QualifierName>administration &#38; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Procarbazine</DescriptorName>
<QualifierName>administration &#38; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Remission, Spontaneous</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Support, U.S. Gov't, P.H.S.</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Vinblastine</DescriptorName>
<QualifierName>administration &#38; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Vincristine</DescriptorName>
<QualifierName>administration &#38; dosage</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
